BAY 80-6946 CAS:1032568-63-0

CAS NO: 1032568-63-0
BAY 80-6946 CAS:1032568-63-0
Description Review
Description

Copanlisib BAY 80-6946 is a small molecule inhibitor that targets the phosphoinositide 3-kinase (PI3K) signaling pathway, which plays a key role in cell growth and survival. It has potential applications in the treatment of various cancers, including lymphoma and solid tumors.

Chemical name: 5-amino-4-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidine-7-carboxamide

Molecular formula: C23H21N5O2

Formula weight: 415.45 g/mol

CAS No: 1032568-63-0

Top ten keywords from Google and Synonyms:

  1. Copanlisib mechanism of action
  2. BAY 80-6946 for lymphoma
  3. PI3K signaling pathway inhibitor
  4. Copanlisib safety profile
  5. Copanlisib side effects
  6. Copanlisib dosing information
  7. Copanlisib drug development
  8. Copanlisib pharmacokinetics
  9. 5-amino-4-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidine-7-carboxamide
  10. CAS number 1032568-63-0

Health benefits of this product: Copanlisib BAY 80-6946 has been shown to be effective in treating relapsed or refractory follicular lymphoma, a type of non-Hodgkin's lymphoma. It may also have potential applications in the treatment of other cancers, including solid tumors.

Potential effects: As a PI3K signaling pathway inhibitor, Copanlisib BAY 80-6946 has the potential to slow or stop tumor growth in various cancers, including lymphoma and solid tumors. It may also have fewer side effects than traditional chemotherapy drugs. However, more research is needed to fully understand the potential effects of Copanlisib BAY 80-6946.

Product mechanism: Copanlisib BAY 80-6946 works by inhibiting the PI3K signaling pathway, which plays a key role in cell growth and survival. In cancer cells, this pathway is often overactive, leading to uncontrolled growth and tumor formation. Copanlisib BAY 80-6946 binds to and blocks the activity of the delta isoform of PI3K, which is involved in the pathway. This leads to a reduction in the activity of the pathway and subsequently slows or stops tumor growth.

Safety: Copanlisib BAY 80-6946 has been shown to be generally safe in clinical studies, but like all drugs, it can cause side effects. Patients should consult their healthcare provider before beginning treatment with Copanlisib BAY 80-6946 to discuss any potential risks or concerns.

Side effects: The most common side effects of Copanlisib BAY 80-6946 include hyperglycemia, diarrhea, fatigue, and hypertension. Other potential side effects may include liver toxicity, respiratory infections, and neutropenia. Patients should report any severe or persistent side effects to their healthcare provider.

Dosing information: Copanlisib BAY 80-6946 dosing varies depending on the indication and patient factors such as age, weight, and overall health. It is typically administered intravenously. Patients should follow their healthcare provider's dosing instructions carefully and report any missed doses or changes in symptoms.

Conclusion: Copanlisib BAY 80-6946 is a promising drug candidate for the treatment of various cancers, including lymphoma and solid tumors. Its ability to inhibit the PI3K signaling pathway makes it a potentially valuable tool in slowing or stopping tumor growth. However, like all drugs, it can cause side effects, and patients should be aware of the potential risks and consult their healthcare provider before beginning treatment with Copanlisib BAY 80-6946

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code